Virology

Chlamydia trachomatis

Moxifloxacin

Mycoplasma genitalium

Antibiotics

Genetics

Medicine

Biology

Microbiology

Antimicrobial Agents and Chemotherapy

Prevalence, trends, and treatment outcome estimates were generated for parC variants in macrolide-resistant Mycoplasma genitalium. Among 539 cases, the most common amino acid change was S83I, which increased from 13% in 2012 to 2013, to 23% in 2019 to 2020 (Ptrend = 0.046). From 381 moxifloxacin treatments, failure occurred in 58.7% (95% confidence interval [CI], 46.7 to 69.9) of cases with S83I. Other changes affecting S83 or D87 were uncommon and minor contributors to failure. The absence of S83I was highly predictive of moxifloxacin cure (96.4%; 95% CI, 93.7 to 98.2), highlighting diagnostic potential.

<i>parC</i> Variants in Mycoplasma genitalium: Trends over Time and Association with Moxifloxacin Failure

parC Variants in Mycoplasma genitalium: Trends over Time and Association with Moxifloxacin Failure